Pharmacyte Biotech, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by Pharmacyte Biotech, Inc. on December 28, 2022. The meeting was conducted via live webcast. A quorum was established with 13,474,962 shares represented, constituting approximately 69.0% of outstanding voting shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on seven proposals. The results are as follows:
- Proposal 1 (Election of Directors): All five nominees (Joshua N. Silverman, Jonathan L. Schechter, Michael M. Abecassis, Robert Weinstein, and Wayne R. Walker) were elected.
- Proposal 2 (2022 Equity Incentive Plan): Approved with 6,532,612 votes For, 1,162,890 Against, and 118,971 Abstain.
- Proposal 3 (Reverse Stock Split): Approved with 11,385,563 votes For, 2,067,045 Against, and 22,354 Abstain. This authorizes the Board to effect a reverse split at a ratio of 1-for-5 to 1-for-20 at their discretion.
- Proposal 4 (Increase Authorized Shares): Approved with 11,020,851 votes For, 2,399,825 Against, and 54,286 Abstain. This amends the Charter to increase authorized common stock from 33,333,334 to 133,333,334 shares.
- Proposal 5 (Ratification of Auditor): Armanino LLP was ratified as the independent registered public accounting firm for the fiscal year ending April 30, 2023, with 13,124,245 votes For.
- Proposal 6 (Executive Compensation): Approved on a non-binding advisory basis with 6,554,590 votes For and 720,564 Against.
- Proposal 7 (Frequency of Compensation Votes): Stockholders voted for annual advisory votes (7,493,683 votes) over biennial or triennial options.
Guidance, Outlook, and Risks
The Board retains discretion on whether and when to implement the reverse stock split (Proposal 3) and the increase in authorized shares (Proposal 4), based on market conditions and trading prices. The Company will disclose its final decision regarding the frequency of future executive compensation votes in an amendment to this report within 150 days of the Annual Meeting.
Key Facts for Investor Verification
- Verify the specific ratio and effective date of the reverse stock split, as the Board has discretion within the 1-for-5 to 1-for-20 range.
- Confirm the filing of the Charter amendment to increase authorized shares to 133,333,334.
- Monitor the upcoming 8-K amendment regarding the final decision on the frequency of executive compensation votes.
- Note that Joshua N. Silverman is serving as Interim Chief Executive Officer and Interim President.